Navigation Links
High-Dose Chemo Helps Beat Rare Brain Cancer
Date:1/30/2008

Many patients achieved long-term remission without radiation, study finds

WEDNESDAY, Jan. 30 (HealthDay News) -- Most people suffering from a rare brain cancer appear to benefit from high doses of the chemotherapy drug methotrexate, a small study finds.

Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma that affects the brain. Although it is typically very difficult to treat, it can be cured or sent into long remissions. Current treatment is often a combination of radiation and chemotherapy. Newer approaches involve giving chemotherapy first, and waiting on radiation until the results of chemotherapy are seen.

However, "A subset of these patients with a rare form of non-Hodgkin lymphoma appeared to be cured by chemotherapy alone," explained lead researcher Dr. Tracy Batchelor, from the Massachusetts General Hospital Cancer Center in Boston.

Batchelor, who is executive director of the Stephen E. & Catherine Pappas Center for Neuro-Oncology at the hospital, noted there are about 1,500 new cases of PCNSL diagnosed in the United States each year.

In the study, Batchelor's group treated 25 adults with newly diagnosed PCNSL with a high dose of methotrexate every two weeks for four months, or until there were no signs of the brain tumor. The patients were followed for a minimum of 6.5 years.

The report appears in the Jan. 29 issue of Neurology.

Batchelor's team found that 52 percent of the patients had a complete remission of their cancer and 40 percent had not had a relapse after seven years. Average survival of all patients who received methotrexate was 4.5 years, compared with one year among patients who had radiation therapy.

It's clear that methotrexate is the best drug to treat this tumor, Batchelor said. "The drug attacks cells that are dividing. Other drugs don't have as high a response rate," he explained.

Batchelor noted that it is unusual for a single drug to achieve remission in cancer.

More studies are needed to find the most effective dose of methotrexate and to find a combination therapy that will produce even better results, Batchelor said. "The question is whether adding other drugs will make patients do better," he said.

"We are looking for drugs that act against lymphoma and actually get into the nervous system," Batchelor said. "We have a new trial where we will be adding three additional drugs to methotrexate. We hope we are going to see even more patients achieve long-term remission."

One expert believes that, based on these findings, methotrexate could save many patients from having to undergo harmful brain radiation.

"Methotrexate is to date the most effective reported drug in primary central nervous system lymphoma," said Dr. Paul Graham Fisher, an associate professor of neurology and the Beirne Family Director of Neuro-Oncology at Packard Hospital at Stanford University.

This is encouraging because in some rare instances patients may not need radiation treatment, Fisher said. "As a cautionary note, the numbers of patients are small, and we need to see greater extension of this work, and also with monitoring patients for leukoencephalopathy (destruction of fibers covering nerve cells), apparently seen more widely when used in children with leukemia," he said.

Methotrexate is commonly used in chemotherapy and is also used in treating autoimmune diseases such as Crohn's disease, psoriasis and arthritis.

More information

For more on primary central nervous system lymphoma, visit the U.S. National Cancer Institute.



SOURCES: Tracy Batchelor, M.D., associate professor, neurology, Harvard University, and executive director, Stephen E. & Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, both in Boston; Paul Graham Fisher, M.D. associate professor, neurology, and the Beirne Family Director of Neuro-Oncology, Packard Hospital, Stanford University, Palo Alto, Calif.; Jan. 29, 2008, Neurology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. High-Dose Chemo Provides Little Benefit to Breast Cancer Patients
2. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
3. Explaining chemotherapy-associated nausea
4. Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors
5. ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
6. Class of Chemotherapy Drugs Helps Certain Breast Cancer Patients
7. Chemotherapy and tamoxifen reduce risk of second breast cancer
8. Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia
9. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
10. Extracellular protein sensitizes ovarian cancer cells to chemotherapy
11. Chemoprevention, naturally: Findings on plant-derived cancer medicines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
High-Dose Chemo Helps Beat Rare Brain Cancer
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: